‘Wait-and-See Time’: Panel Predicts Limited Congressional Action On Devices This Year
An expert panel at the FDLI annual meeting expects the US Congress to want to see more results from recent legislation on devices before it moves ahead with further FDA reform. Though, pandemic-related measures remain a priority.
You may also be interested in...
The FDA updated its policies regarding 506J notifications for device manufacturers at the end of the public health emergency.
Medtech groups call for extended commentary and compliance periods for two new EtO regulations from the EPA.
At the first meeting of the Capitol Hill steering committee on pandemic preparedness, experts weighed in on what they hope to see in PAHPA’s reauthorization.